التفاصيل البيبلوغرافية
| العنوان: |
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm |
| المؤلفون: |
Keller, Alana L., Sherbenou, Daniel W., Forsberg, Peter A., Mark, Tomer M. |
| المصدر: |
Frontiers in Oncology ; volume 12 ; ISSN 2234-943X |
| بيانات النشر: |
Frontiers Media SA |
| سنة النشر: |
2022 |
| المجموعة: |
Frontiers (Publisher - via CrossRef) |
| مصطلحات موضوعية: |
Cancer Research, Oncology |
| الوصف: |
Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of remission and relapse proceed as long as patients have new lines of therapy available to them. This reality has prompted development of many novel immunotherapeutics. Many of these drugs exploit the cytotoxic capabilities of the patients’ own T cells, effectively redirecting them to myeloma cells that are otherwise evading immune attack. Approaches including CAR T cell therapy and bispecific antibodies have displayed impressive efficacy in clinical trials for myeloma patients. This review examines the different approaches that utilize T cells in multiple myeloma therapy and investigates the benefits and risks of these exciting new strategies. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
unknown |
| DOI: |
10.3389/fonc.2022.925818 |
| DOI: |
10.3389/fonc.2022.925818/full |
| الإتاحة: |
https://doi.org/10.3389/fonc.2022.925818Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.AE8896B3 |
| قاعدة البيانات: |
BASE |
